QSI250117P1500
- 0.02
- 0.000.00%
Quantum-Si Newsroom
Quantum-Si Analyst Ratings
H.C. Wainwright Maintains Quantum-Si(QSI.US) With Buy Rating, Maintains Target Price $5.5
Quantum-Si's Promising Outlook With Platinum Pro Launch and Buy Rating Justification
CCORF Maintains Quantum-Si(QSI.US) With Hold Rating, Maintains Target Price $1
H.C. Wainwright Maintains Quantum-Si(QSI.US) With Buy Rating, Raises Target Price to $5.5
Quantum-Si Is Maintained at Buy by HC Wainwright & Co.
Quantum-Si's Strategic Advancements and Innovations Drive Buy Rating
Quantum-Si Analyst Ratings
Quantum-Si Price Target Cut to $1.00/Share From $1.50 by Canaccord Genuity
Quantum-Si Is Maintained at Hold by Canaccord Genuity
HC Wainwright & Co. Reiterates Buy on Quantum-Si, Maintains $4 Price Target
Quantum-Si Analyst Ratings
CCORF Maintains Quantum-Si(QSI.US) With Hold Rating, Cuts Target Price to $1
Buy Rating Affirmed for Quantum-Si on Strong Financials and Promising Product Pipeline
Analysts Offer Insights on Healthcare Companies: Quantum-Si (QSI), Savara (SVRA) and Ventyx Biosciences (VTYX)
Quantum-Si Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Quantum-Si, Maintains $4 Price Target
Analysts Offer Insights on Healthcare Companies: Privia Health Group (PRVA), Revance Therapeutics (RVNC) and Quantum-Si (QSI)
Quantum-Si: A Balanced Hold Rating Amidst Early-Stage Commercialization and Innovation
Quantum-Si Analyst Ratings